STATCenter·
STAT+: GSK sees its return to cancer start to pay off
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
Read at STAT →
Health · 1 sources covering this
STAT+: GSK sees its return to cancer start to pay off
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
Coverage spectrum
0 L · 1 C · 0 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/5b18ef042eed60e79fe89b429d5eecc6e1f9d628" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: GSK sees its return to cancer start to pay off"></iframe>
